These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35976565)

  • 1. Long-acting injectable PLGA/PLA depots for leuprolide acetate: successful translation from bench to clinic.
    Abulateefeh SR
    Drug Deliv Transl Res; 2023 Feb; 13(2):520-530. PubMed ID: 35976565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leuprolide Acetate for Puberty Suppression in Transgender and Gender Diverse Youth: A Comparison of Subcutaneous Eligard Versus Intramuscular Lupron.
    Eitel KB; Hodax JK; DiVall S; Kidd KM; Salehi P; Sequeira GM
    J Adolesc Health; 2023 Feb; 72(2):307-311. PubMed ID: 36404242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic (60-week) toxicity study of DUROS leuprolide implants in dogs.
    Cukierski MJ; Johnson PA; Beck JC
    Int J Toxicol; 2001; 20(6):369-81. PubMed ID: 11797819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide.
    Zhou J; Walker J; Ackermann R; Olsen K; Hong JKY; Wang Y; Schwendeman SP
    Mol Pharm; 2020 May; 17(5):1502-1515. PubMed ID: 32074448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group.
    Dlugi AM; Miller JD; Knittle J
    Fertil Steril; 1990 Sep; 54(3):419-27. PubMed ID: 2118858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks.
    Bowen RL; Perry G; Xiong C; Smith MA; Atwood CS
    J Alzheimers Dis; 2015; 44(2):549-60. PubMed ID: 25310993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters.
    Luan X; Bodmeier R
    Eur J Pharm Sci; 2006 Feb; 27(2-3):143-9. PubMed ID: 16243496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant.
    Ravivarapu HB; Moyer KL; Dunn RL
    AAPS PharmSciTech; 2000 Feb; 1(1):E1. PubMed ID: 14727850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation.
    Park K; Skidmore S; Hadar J; Garner J; Park H; Otte A; Soh BK; Yoon G; Yu D; Yun Y; Lee BK; Jiang X; Wang Y
    J Control Release; 2019 Jun; 304():125-134. PubMed ID: 31071374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterostereocomplexes prepared from d-PLA and l-PLA and leuprolide. II. Release of leuprolide.
    Slager J; Domb AJ
    Biomacromolecules; 2003; 4(5):1316-20. PubMed ID: 12959600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eligard: leuprolide acetate in a novel sustained-release delivery system.
    Sartor O
    Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.
    Hornstein MD; Surrey ES; Weisberg GW; Casino LA
    Obstet Gynecol; 1998 Jan; 91(1):16-24. PubMed ID: 9464714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nature of peptide interactions with acid end-group PLGAs and facile aqueous-based microencapsulation of therapeutic peptides.
    Sophocleous AM; Desai KG; Mazzara JM; Tong L; Cheng JX; Olsen KF; Schwendeman SP
    J Control Release; 2013 Dec; 172(3):662-70. PubMed ID: 24021356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references.
    Leitner JM; Mayr FB; Spiel AO; Firbas C; Savulsky C; Mis R; Corrado ME; Jilma B
    Int J Clin Pharmacol Ther; 2008 Aug; 46(8):407-14. PubMed ID: 18793582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing formulation parameters for the development of carvedilol injectable
    Alrashdan M; Shraideh ZA; Abulateefeh SR
    Pharm Dev Technol; 2023 Nov; 28(9):865-876. PubMed ID: 37795865
    [No Abstract]   [Full Text] [Related]  

  • 18. Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group.
    Wheeler JM; Knittle JD; Miller JD
    Am J Obstet Gynecol; 1993 Jul; 169(1):26-33. PubMed ID: 8333471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New long-acting injectable microspheres prepared by IVL-DrugFluidic™ system: 1-month and 3-month in vivo drug delivery of leuprolide.
    Kim M; Kim JH; Kim S; Maharjan R; Kim NA; Jeong SH
    Int J Pharm; 2022 Jun; 622():121875. PubMed ID: 35636628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres.
    Andhariya JV; Jog R; Shen J; Choi S; Wang Y; Zou Y; Burgess DJ
    J Control Release; 2019 Aug; 308():1-13. PubMed ID: 31301338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.